Developer docs
API playgroundTry for free, no card

Search company profiles

Kibion

Full company profile

uuid0027nce

Namestring
Kibion
Legal namestring
Kibion GmbH
Websiteurl
kibion.com
Company typeenum
Private
Founded yearint
2011
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRueil-malmaison, France
HQ citystring
Rueil-malmaison
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
urea breath tests, Helicobacter pylori diagnostics, 13C isotope analyzers, in vitro diagnostics, medical diagnostic devices
Industry1 code
PRIMARYHLAAAFAH
Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal)
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Surgical & Medical Instruments & Apparatus3841
Product category
In Vitro Diagnostics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Diagnostic Instruments
TypeHardware Sales
Description

Sale of diagnostic instruments including Kibion Dynamic analyzers and Heliprobe System analyzers. Instruments are sold to hospitals, laboratories, and doctor's offices through distributor network.

kibion.com
2Consumables and Test Kits
TypeTransaction Fee
Description

Recurring revenue from sale of consumables including Diabact UBT tablets, BreathCards, BreathBags, and Mouthpieces used with diagnostic instruments.

kibion.com
3Service and Support
TypeSubscription Recurring
Description

Annual service contracts and support for Kibion Dynamic instruments including calibration, maintenance, and technical support.

kibion.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Kibion Dynamic
Description

A leading instrument for quantitative diagnosis of breath tests, employing non-radioactive 13C-labelled stable isotope based on infra-red technology. Previously known as IRIS Dynamic.

kibion.com
+2 more records
Core offering1 text field

Kibion manufactures and supplies diagnostic instruments and consumables for non-invasive detection of Helicobacter pylori (H. pylori), the bacterium implicated in gastric ulcers and gastric cancer. Its portfolio includes the Kibion Dynamic 13C-urea breath test analyzer (ND-IR spectroscopy), the Heliprobe System (14C-urea with Geiger-Müller counter), and the Diabact UBT 50mg tablet consumable, sold to hospitals, laboratories, and physician offices in 60+ countries through a distributor network.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Diabact UBT achieves 98% sensitivity and 100% specificity for H. pylori detection
+2 more records
Product overview1 text field

Kibion is a diagnostic company and global leader in complete solutions for rapid, reliable urea breath tests to diagnose Helicobacter pylori (the stomach ulcer bacterium). The product portfolio consists of two main diagnostic platforms: (1) the Kibion Dynamic infrared isotope analyzer system (formerly IRIS Dynamic) which uses non-radioactive 13C-urea breath testing with ND-IR spectroscopy, and (2) the Heliprobe System which uses C14-urea capsules with Geiger-Müller counter technology. Both systems are used with the Diabact UBT 50mg tablet formulation. The Kibion Dynamic can be extended with the Dynamic Pro unit for higher throughput. All products are designed for use in laboratories, hospitals, and doctor offices.

Product and service6 records
1Kibion Dynamic
CategoryDiagnostic instrument
Description

Infrared isotope analyzer for quantitative diagnosis of breath tests. Measures 13CO2 and 12CO2 concentrations from breath samples using non-dispersive IR spectroscopy (ND-IR) technology. Designed for hospitals, laboratories, and doctor offices conducting non-invasive H. pylori testing.

2Heliprobe System
CategoryDiagnostic instrument
Description

Portable diagnostic system using C14-urea capsules (HeliCap) and a Geiger-Müller counter-based analyzer for rapid H. pylori detection. Provides easy, inexpensive analysis that can be operated by non-specialists, suitable for point-of-care clinical settings.

3Diabact UBT
CategoryDiagnostic consumable
Description

50 mg tablet formulation for urea breath testing. Features 10-minute sampling time, 100% specificity and 98% sensitivity. No test meal required - just swallow tablet with water. Used as the consumable substrate with Kibion Dynamic and Heliprobe instruments.

4HeliCap
CategoryDiagnostic consumable
Description

C14-urea capsule consumable for the Heliprobe System. Contains extremely low levels of radioactivity (1 microCurie), no special shielding required for shipping.

5Heliprobe BreathCard
CategoryDiagnostic consumable
Description

Sample collection card used with the Heliprobe System to capture breath samples for H. pylori analysis.

6BreathBag
CategoryDiagnostic consumable
Description

Single or double breath sample bags for the Kibion Dynamic. Standard volume of 120 ml allows two measurements per sample.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Mayoly Spindler acquired Kibion in October 2016 to become the leading manufacturer of Urea Breath Tests globally. The acquisition generates synergies in gastroenterology where Mayoly Spindler has strong product portfolio. Kibion operates as a company of Mayoly with access to their gastro field expertise and pipeline products.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive distributor for Kibion products in the Gulf Region. Presented Kibion Dynamic at Arab Health Exhibition and Congress. Handles sales and distribution throughout Middle East market.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Contract manufacturing organization (CMO) in Spain that assumed production of Diabact UBT tablets in 2015 after transfer from Orexo's facilities in Sweden. Production successfully transferred with smooth transition.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

German company acquired by Kibion in 2011, manufacturer of IRIS instruments for diagnostic breath tests. Acquisition turned Kibion into complete solutions provider of both diagnostic breath tests and instruments. WAT became Kibion GmbH in November 2014.

5Analytical Services International Ltd
Strategic tierMinorTypeOthers
Description

Laboratory located at St George's University of London designated as the analysis facility for UK patient samples from April 2013, replacing Glasgow Royal Infirmary. Provides on-line reporting services for test results.

kibion.com
Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major diagnostics and women's health company with molecular and immunoassay capabilities applicable to GI pathogens. A broad incumbent operating in clinical diagnostics infrastructure comparable to Kibion's lab/hospital customer channels.

TypeBroad incumbent
Description

Italian IVD company focused on specialty diagnostics including gastro and infectious disease assays. A broader incumbent with comparable hospital/lab customer base and H. pylori-relevant diagnostic menu.

TypeDirect peer
Description

Makes and markets 13C-urea breath test devices (e.g., POCone, UBiT) for H. pylori diagnosis globally. A direct UBT instrument competitor with broader pharma scale and Asia-Pacific distribution strength overlapping Kibion's served markets.

TypeBroad incumbent
Description

US-based diagnostics company with H. pylori stool antigen tests and the BreathID UBT platform (via Exalenz). A broader IVD incumbent that overlaps with Kibion in H. pylori diagnostics across multiple modalities.

TypeDirect peer
Description

Finnish diagnostics company with a UBT-based H. pylori diagnostic (PyloriTek) and broader GI diagnostic portfolio. A direct niche peer in UBT and gastro diagnostics targeting hospitals and labs similar to Kibion's customer base.

TypeOthers
Description

Spanish contract development and manufacturing organization (CDMO) that has produced Diabact UBT tablets for Kibion since 2016. Closest enabling/supply-chain partner rather than a competitor, but materially relevant to the diagnostic consumables manufacturing ecosystem.

TypeBroad incumbent
Description

Specialty diagnostics company with infectious disease testing including H. pylori assays. A broad incumbent peer in IVD with overlapping customer base in hospitals and reference labs.

8Abbott Laboratories
TypeBroad incumbent
Description

Major diagnostics incumbent with H. pylori immunoassay and other GI diagnostic products sold to hospitals and labs globally. Broad incumbent in IVD serving similar customer base but not specialized in UBT.

TypeDirect peer
Description

Exalenz developed the BreathID system, a direct competitor to Kibion Dynamic for 13C-urea breath testing for H. pylori. Acquired by Meridian Bioscience, the combined entity is the most directly comparable UBT-focused peer to Kibion.

TypeDirect peer
Description

Kibion's parent company and a French pharma with a strong gastroenterology product portfolio. Directly comparable as a GI-focused specialty pharma/diagnostics group and the most relevant strategic-owner peer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kibion

In Vitro Diagnosticskibion.com

Kibion firmographics

Firmographics
Name
Kibion
Legal name
Kibion GmbH
Website
https://kibion.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Kibion industry classification

Industry
Product category
In Vitro Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical Equipment and Supplies Manufacturing (3391)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAAFAH
Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal)

Keywords

  • Urea breath tests
  • Helicobacter pylori diagnostics
  • 13C isotope analyzers
  • In vitro diagnostics
  • Medical diagnostic devices

Where Kibion is headquartered

Location

Headquarters

HQ city
Rueil-malmaison
HQ country
France
HQ region
Europe

Offices2 records

Markets served

Kibion business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Diagnostic Instruments: Sale of diagnostic instruments including Kibion Dynamic analyzers and Heliprobe System analyzers. Instruments are sold to hospitals, laboratories, and doctor's offices through distributor network.
  2. Consumables and Test Kits: Recurring revenue from sale of consumables including Diabact UBT tablets, BreathCards, BreathBags, and Mouthpieces used with diagnostic instruments.
  3. Service and Support: Annual service contracts and support for Kibion Dynamic instruments including calibration, maintenance, and technical support.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Kibion product offering

Product offering

Core offering

Kibion manufactures and supplies diagnostic instruments and consumables for non-invasive detection of Helicobacter pylori (H. pylori), the bacterium implicated in gastric ulcers and gastric cancer. Its portfolio includes the Kibion Dynamic 13C-urea breath test analyzer (ND-IR spectroscopy), the Heliprobe System (14C-urea with Geiger-Müller counter), and the Diabact UBT 50mg tablet consumable, sold to hospitals, laboratories, and physician offices in 60+ countries through a distributor network.

Product overview

Kibion is a diagnostic company and global leader in complete solutions for rapid, reliable urea breath tests to diagnose Helicobacter pylori (the stomach ulcer bacterium). The product portfolio consists of two main diagnostic platforms: (1) the Kibion Dynamic infrared isotope analyzer system (formerly IRIS Dynamic) which uses non-radioactive 13C-urea breath testing with ND-IR spectroscopy, and (2) the Heliprobe System which uses C14-urea capsules with Geiger-Müller counter technology. Both systems are used with the Diabact UBT 50mg tablet formulation. The Kibion Dynamic can be extended with the Dynamic Pro unit for higher throughput. All products are designed for use in laboratories, hospitals, and doctor offices.

Differentiator

Problem solved

Functional benefit

Brands

  • Kibion Dynamic: A leading instrument for quantitative diagnosis of breath tests, employing non-radioactive 13C-labelled stable isotope based on infra-red technology. Previously known as IRIS Dynamic.
  • Heliprobe System
  • Diabact UBT

Products and services

  • Kibion Dynamic Infrared isotope analyzer for quantitative diagnosis of breath tests. Measures 13CO2 and 12CO2 concentrations from breath samples using non-dispersive IR spectroscopy (ND-IR) technology. Designed for hospitals, laboratories, and doctor offices conducting non-invasive H. pylori testing.
  • Heliprobe System Portable diagnostic system using C14-urea capsules (HeliCap) and a Geiger-Müller counter-based analyzer for rapid H. pylori detection. Provides easy, inexpensive analysis that can be operated by non-specialists, suitable for point-of-care clinical settings.
  • Diabact UBT 50 mg tablet formulation for urea breath testing. Features 10-minute sampling time, 100% specificity and 98% sensitivity. No test meal required - just swallow tablet with water. Used as the consumable substrate with Kibion Dynamic and Heliprobe instruments.
  • HeliCap C14-urea capsule consumable for the Heliprobe System. Contains extremely low levels of radioactivity (1 microCurie), no special shielding required for shipping.
  • Heliprobe BreathCard Sample collection card used with the Heliprobe System to capture breath samples for H. pylori analysis.
  • BreathBag Single or double breath sample bags for the Kibion Dynamic. Standard volume of 120 ml allows two measurements per sample.

Quantifiable outcome

  • Diabact UBT achieves 98% sensitivity and 100% specificity for H. pylori detection
  • +2 more outcomes

Companies that use Kibion

Customer profile

Named customers3 records

Segments1 record

Ideal customer profiles1 record

Kibion technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

Feature4 records

Kibion partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Mayoly Spindler (Laboratory Mayoly Spindler)coreStrategic or Co-development PartnerMayoly Spindler acquired Kibion in October 2016 to become the leading manufacturer of Urea Breath Tests globally. The acquisition generates synergies in gastroenterology where Mayoly Spindler has strong product portfolio. Kibion operates as a company of Mayoly with access to their gastro field expertise and pipeline products.
  • Gulf Drug EstablishmentcoreChannel Partner/ Reseller/ DistributorExclusive distributor for Kibion products in the Gulf Region. Presented Kibion Dynamic at Arab Health Exhibition and Congress. Handles sales and distribution throughout Middle East market.
  • IdifarmacoreOEM/ Whitelabel/ Licensing PartnerContract manufacturing organization (CMO) in Spain that assumed production of Diabact UBT tablets in 2015 after transfer from Orexo's facilities in Sweden. Production successfully transferred with smooth transition.
  • Wagner Analysen Technik GmbH (WAT)coreStrategic or Co-development PartnerGerman company acquired by Kibion in 2011, manufacturer of IRIS instruments for diagnostic breath tests. Acquisition turned Kibion into complete solutions provider of both diagnostic breath tests and instruments. WAT became Kibion GmbH in November 2014.
  • Analytical Services International LtdminorOthersLaboratory located at St George's University of London designated as the analysis facility for UK patient samples from April 2013, replacing Glasgow Royal Infirmary. Provides on-line reporting services for test results.

Scale indicators7 records

Recent moves10 records

Expansion highlights5 records

Kibion competitors and assessment

Company assessment

Broad incumbents

  • Hologic: Major diagnostics and women's health company with molecular and immunoassay capabilities applicable to GI pathogens. A broad incumbent operating in clinical diagnostics infrastructure comparable to Kibion's lab/hospital customer channels.
  • DiaSorin: Italian IVD company focused on specialty diagnostics including gastro and infectious disease assays. A broader incumbent with comparable hospital/lab customer base and H. pylori-relevant diagnostic menu.
  • Meridian Bioscience: US-based diagnostics company with H. pylori stool antigen tests and the BreathID UBT platform (via Exalenz). A broader IVD incumbent that overlaps with Kibion in H. pylori diagnostics across multiple modalities.
  • QuidelOrtho: Specialty diagnostics company with infectious disease testing including H. pylori assays. A broad incumbent peer in IVD with overlapping customer base in hospitals and reference labs.
  • Abbott Laboratories: Major diagnostics incumbent with H. pylori immunoassay and other GI diagnostic products sold to hospitals and labs globally. Broad incumbent in IVD serving similar customer base but not specialized in UBT.

Direct peers

  • Otsuka Pharmaceutical: Makes and markets 13C-urea breath test devices (e.g., POCone, UBiT) for H. pylori diagnosis globally. A direct UBT instrument competitor with broader pharma scale and Asia-Pacific distribution strength overlapping Kibion's served markets.
  • Biohit Oyj: Finnish diagnostics company with a UBT-based H. pylori diagnostic (PyloriTek) and broader GI diagnostic portfolio. A direct niche peer in UBT and gastro diagnostics targeting hospitals and labs similar to Kibion's customer base.
  • Exalenz Bioscience (acquired by Meridian Bioscience): Exalenz developed the BreathID system, a direct competitor to Kibion Dynamic for 13C-urea breath testing for H. pylori. Acquired by Meridian Bioscience, the combined entity is the most directly comparable UBT-focused peer to Kibion.
  • Mayoly Spindler Laboratories: Kibion's parent company and a French pharma with a strong gastroenterology product portfolio. Directly comparable as a GI-focused specialty pharma/diagnostics group and the most relevant strategic-owner peer.

Others

  • Idifarma: Spanish contract development and manufacturing organization (CDMO) that has produced Diabact UBT tablets for Kibion since 2016. Closest enabling/supply-chain partner rather than a competitor, but materially relevant to the diagnostic consumables manufacturing ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Kibion compliance and trust

Trust signal

Compliance2 records

Kibion financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kibion leadership team

Management profile

Number of profiles

Profiles3 records

Kibion subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Kibion funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kibion M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kibion

What does Kibion do?

Kibion manufactures and supplies diagnostic instruments and consumables for non-invasive detection of Helicobacter pylori (H. pylori), the bacterium implicated in gastric ulcers and gastric cancer. Its portfolio includes the Kibion Dynamic 13C-urea breath test analyzer (ND-IR spectroscopy), the Heliprobe System (14C-urea with Geiger-Müller counter), and the Diabact UBT 50mg tablet consumable, sold to hospitals, laboratories, and physician offices in 60+ countries through a distributor network.

Is Kibion a public or private company?

Kibion is a private company. It is classified as corporate owned and is currently operating.

When was Kibion founded?

Kibion was founded in 2011. It employs 11 to 50 people.

Where is Kibion based?

Kibion is headquartered in Rueil-malmaison, France, in the Europe region.

How does Kibion make money?

Three revenue lines are on record. Diagnostic Instruments are the primary driver. The others are consumables and Test Kits and service and Support.

Who are Kibion's main competitors?

Broad incumbents on record are Hologic, DiaSorin, Meridian Bioscience, QuidelOrtho and Abbott Laboratories. Direct peers are Otsuka Pharmaceutical, Biohit Oyj, Exalenz Bioscience (acquired by Meridian Bioscience) and Mayoly Spindler Laboratories. Idifarma is listed as an others.

Does Kibion have an API?

No public API is recorded for Kibion.

What industry is Kibion in?

Kibion's product category is In Vitro Diagnostics. Its primary akta.pro industry code is HLAAAFAH, Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireArab Health Exhibition & Congress: Kibions nya instrument möter behoven hos laboratorier, sjukhus och vårdcentraler av snabb och tillförlitlig diagnostik av Helicobacter pylori-infektionerKibion AB is launching its new Kibion® Dynamic instrument for diagnosing Helicobacter pylori infections, with Gulf Drug Establishment presenting the device at the Arab Health exhibition in Dubai. The system utilizes infrared technology and offers scalable capacity through the Kibion® Dynamic Pro add-on to meet varying laboratory needs. Kibion anticipates market growth driven by pharmaceutical developments in H. pylori treatments.PR NewswireArab Health Exhibition & Congress: Kibion's New Instrument Meets the Needs of Laboratories, Hospitals and Doctor's Offices for Rapid and Reliable Diagnosis of Helicobacter pylori InfectionsKibion AB, a Swedish diagnostics company, is launching its new Kibion Dynamic instrument for rapid detection of Helicobacter pylori infections using 13C-labelled stable isotopes and infra-red technology, with upscaling capability through the Kibion Dynamic Pro extension device. Gulf Drug Establishment, Kibion's exclusive distributor in the Gulf Region, is presenting the product at the Arab Health Exhibition in Dubai from January 25-28, 2016. The company estimates the overall market for Urea Breath Tests will grow as the pharma industry develops new treatment options for H. pylori infections, indicating unmet medical needs for both improved treatments and reliable diagnosis.PR NewswireArab Health Exhibition & Congress: Kibions neues Instrument erfüllt den Bedarf von Laboren, Krankenhäusern und Arztpraxen hinsichtlich einer raschen und zuverlässigen Diagnose von Helicobacter pylori-Swedish diagnostic company Kibion AB launched its new Kibion Dynamic instrument, which uses infrared technology for 13C-labeled stable isotopes to diagnose Helicobacter pylori infections, at the Arab Health Exhibition in Dubai from January 25–28, 2016. The product, scalable via the Kibion Dynamic Pro extension unit and paired with the Diabact UBT tablet, is being distributed exclusively in the Gulf region by Gulf Drug Establishment. Kibion projects continued growth in the urease breath test market driven by increased pharmaceutical interest in new H. pylori treatment options.PR NewswireArab Health Exhibition & Congress: nuevo instrumento de Kibion para diagnóstico de infecciones por Helicobacter pyloriSwedish diagnostic company Kibion AB launched its new Kibion Dynamic instrument for rapid and reliable diagnosis of Helicobacter pylori infections using 13C stable isotope infrared technology. The product was presented at the Arab Health Exhibition & Congress in Dubai from January 25-28, 2016, with Gulf Drug Establishment as the exclusive distributor showcasing the instrument. Kibion estimates the urea breath test market will grow as pharmaceutical companies develop new treatment options for H. pylori infections.PR NewswireArab Health Exhibition & Congress : le nouveau dispositif de Kibion répond aux besoins de diagnostic rapide et fiable des infections à Helicobacter pylori des laboratoires, hôpitaux et cabinets médicaKibion AB, a Swedish medical diagnostics company, is launching its new Kibion Dynamic device for urea breath testing to detect Helicobacter pylori infections, which can cause stomach ulcers. The device features a touchscreen interface and can be expanded with the Kibion Dynamic Pro accessory to handle increased testing volumes for laboratories, hospitals, and medical practices. Gulf Drug Establishment, Kibion's exclusive distributor in the Gulf region, will showcase the product at the Arab Health Exhibition in Dubai from January 25-28, 2016.GlobeNewswireOrexo takes leading position in diagnostic breath tests through acquisitionOrexo AB acquired German company Wagner Analysen Technik GmbH via its subsidiary Kibion AB, paying 1.4 million EUR. The purchase gives Kibion a leading position in Helicobacter pylori breath tests and access to WAT's IRIS instruments. The acquisition is expected to boost results within 12 months.GlobeNewswireOrexo strengthens its subsidiary Kibion by recruiting Petter Bäckgren as CEOOrexo appointed Petter Bäckgren as CEO of its diagnostic subsidiary Kibion, effective November 15, 2010. Bäckgren previously served as General Manager of clinical diagnostics at DiaSorin and held sales roles at Novartis. He replaces acting CEO Erik Bergman, who will leave to pursue other interests.